ArticleClinical ophthalmology (Auckland, N.Z.)2021

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema.

Nasser G Alsaedi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.